MATF Antibody Engineering Services
Once the heavy-chain variable, (VH), and light-chain variable, (VL), gene sequences have been obtained from a hybridoma, it is possible to optimise the monoclonal antibody’s properties through antibody engineering approaches. At MATF, we offer a range of antibody engineering services including:
- Design and production of antibody fragments (Fab; Fab’2; scFvs)
- Isotype switching and modification of Fc domains to confer or eliminate antibody-dependent cellular cytotoxicity, (ADCC)
- Antibody humanization
- Antibody affinity maturation
- Bispecific antibody design and production.
Please contact Dr Hayley Ramshaw to discuss your Antibody Engineering project needs
Antibody humanization aims to reduce the immunogenicity of monoclonal antibodies from xenogeneic origin by replacing non-human framework regions, (FR), with human ones. It is a crucial step in therapeutic antibody development.
The Fc portion of an antibody determines the isotype of the, molecule and confers effector functions such as antibody-dependent cellular cytotoxicity (ADCC). In most cases it is desirable to for therapeutic antibodies to lack Fc effector functions such as ADCC.
Affinity maturation is the process to improve antibody affinity for an antigen. In vivo, natural affinity maturation by the immune system takes place by somatic hypermutation and clonal selection in the germinal centre. We developed a technology that mimics this process in vitro.
Bispecific antibodies have become increasingly of interest for therapeutic applications. While natural antibodies are monospecific, bispecific antibodies can recognize two different epitopes either on the same or on different antigens. The approach we use at MATF is the fusion of a scFv at the C-terminus of the antibody, thus generating a molecule that binds one antigen at the N-terminus of the molecule and a second antigen at the C-terminus.